Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
Retrieved on:
Thursday, September 16, 2021
Research, Medical Devices, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ACT, Conjugation, Program, Annual Meetings of the International Monetary Fund and the World Bank Group, Immunotherapy, Cell, Biotechnology, Mouse, CEO, Inflammatory bowel disease, Animal, ESMO, Maitansine, Alpha-fetoprotein, Rest, Multiple sclerosis, European Society for Medical Oncology, Neoplasm, Survival, Myasthenia gravis, Toxicity, SRI, Annual general meeting, Southern Research, AFP, Cancer, Oncology, Bone marrow, Vaccine, Medical imaging, ACT-903, Alpha Cancer Technologies, Inc., ACT-903, ALPHA CANCER TECHNOLOGIES, INC.
The preclinical findings we have reported with ACT-903 validates our approach and we look forward to advancing this program into the clinic.
Key Points:
- The preclinical findings we have reported with ACT-903 validates our approach and we look forward to advancing this program into the clinic.
- Alpha Cancer Technologies, Inc. is an emerging biotechnology company with products under development in immunotherapy (Inflammatory Bowel Disease, Multiple Sclerosis, Myasthenia Gravis, Hashimoto) and immuno-oncology.
- ACTs immuno-oncology products target AFP receptors expressed on almost all solid and liquid tumors and immune suppressor cells but absent on normal cells.
- This approach offers the benefits of much lower toxicity and greater efficacy compared to conventional chemotherapy and other targeted therapies.